Purchase this article with an account.
Jessica Maslin, Robert Noecker; Micropulse Trans-scleral Cyclophotocoagulation for the Treatment of Glaucoma. Invest. Ophthalmol. Vis. Sci. 2016;57(12):6478.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the efficacy and safety of Micropulse trans-scleral cyclophotocoagulation for the treatment of glaucoma.
45 glaucoma patients (45 eyes) were recruited. Retrobulbar block was given. Micropulse trans-scleral cyclophotocoagulation was given using the Micropulse P3 device at 2.0 Watts, with a total duration of 70-90 seconds per hemisphere for a total time of 140-180 seconds, at a 31.3% duty cycle. If retreatment was needed, the same treatment parameters were used for retreatment with an increase in duration to a maximum of 180 seconds. Patients were given post-operative medications including topical steroids QID with a taper over a month. IOP lowering medications were withdrawn as indicated. Patients were seen at post-operative day 1, post-operative week 1, and post-operative month 1, 3, 6, and 12. Follow up time was at least one year. Hypotony was defined as an IOP less than 6 mmHg.
25 of the 45 patients were female. Average age was 68.2 years. Mean follow up time was 14.1 months. Mean pre-operative IOP was 28.1 mmHg +/- 5.2. Mean post-operative IOP at 12 months was 16.4 mmHg +/- 4.1. Mean medications used were 3.2 medications preoperatively and 1.1 medications post-operatively. 10 patients needed more than one treatment. The most common side effect was anterior chamber cell at one week. No anterior chamber cell was observed in any patient at the 12 month follow up time. No long term hypotony was observed.
Micropulse trans-scleral cyclophotocoagulation may be a safe and effective treatment for glaucoma.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only